4 results
425
ORKA
Oruka Therapeutics Inc.
9 Aug 24
Business combination disclosure
8:35am
probabilities reflect all patients, and do not exclude Asian ethnicity Induction phase (0 - 16 weeks) Steady - state phase (40 - 52 weeks) 0 20 40 60 80 100 0
425
ORKA
Oruka Therapeutics Inc.
6 Jun 24
Business combination disclosure
4:45pm
- estimated probabilities reflect all patients, and do not exclude Asian ethnicity ORKA - 001 projected to extend exposure - response relationship
425
ORKA
Oruka Therapeutics Inc.
3 Apr 24
Business combination disclosure
7:33am
not exclude Asian ethnicity ORKA-001 projected to extend exposure-response relationship established by Skyrizi Phase III and KNOCKOUT Induction phase
8-K
EX-99.2
ORKA
Oruka Therapeutics Inc.
3 Apr 24
ARCA biopharma and Oruka Therapeutics Announce Merger Agreement
7:31am
all patients, and do not exclude Asian ethnicity ORKA-001 projected to extend exposure-response relationship established by Skyrizi Phase III
- Prev
- 1
- Next